We are live on ! Find out more
CC

Casdin Capital Portfolio holdings

AUM $1.32B
1-Year Est. Return 76.62%
This Fund
S&P 500
This Quarter Est. Return
-26.27%
1 Year Est. Return
+76.62%
3 Year Est. Return
+218.92%
5 Year Est. Return
+86.82%
10 Year Est. Return
+4,823.46%
AUM
$2.23B
AUM Growth
-$1.32B
Cap. Flow
-$302M
Cap. Flow %
-13.54%
Top 10 Hldgs %
55.24%
Holding
55
New
2
Increased
1
Reduced
7
Closed
8

Top Buys

Rank Stock Value
1
TWST icon
Twist Bioscience
TWST
+$11.6M
2
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$10.5M
3
TSVT
2seventy bio
TSVT
+$10.4M

Top Sells

Rank Stock Value
1
CDXS icon
Codexis
CDXS
+$83.5M
2
EXAS
Exact Sciences
EXAS
+$51.9M
3
SRPT icon
Sarepta Therapeutics
SRPT
+$42.1M
4
ALLO icon
Allogene Therapeutics
ALLO
+$39.5M
5
ALEC icon
Alector
ALEC
+$34.1M

Sector Composition

Rank Sector Weight
1 Healthcare 95.64%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BLFS icon
1
BioLife Solutions
BLFS
$1.56B
$172M 7.71%
7,566,292
– –
ALNY icon
2
Alnylam Pharmaceuticals
ALNY
$29.1B
$163M 7.32%
1,000,000
– –
EQRX
3
DELISTED
EQRx, Inc. Common Stock
EQRX
$163M 7.32%
39,527,669
– –
FATE icon
4
Fate Therapeutics
FATE
$294M
$132M 5.91%
3,400,000
– –
RLAY icon
5
Relay Therapeutics
RLAY
$4.04B
$115M 5.18%
3,857,253
– –
SLGC
6
DELISTED
SomaLogic, Inc. Class A Common Stock
SLGC
$99.4M 4.46%
12,389,082
– –
BPMC
7
DELISTED
Blueprint Medicines
BPMC
$99M 4.44%
1,550,000
– –
MXCT icon
8
MaxCyte
MXCT
$116M
$97.7M 4.38%
13,971,334
– –
NVTA
9
DELISTED
Invitae Corporation
NVTA
$97.3M 4.36%
12,203,669
– –
EXAS
10
DELISTED
Exact Sciences
EXAS
$93M 4.17%
1,330,000
-710,000
-35% -$51.9M
PACB icon
11
Pacific Biosciences
PACB
$441M
$72.7M 3.26%
7,990,652
– –
VERV
12
DELISTED
Verve Therapeutics
VERV
$71.6M 3.21%
3,138,167
– –
ABSI icon
13
Absci
ABSI
$1.34B
$65.1M 2.92%
7,718,593
– –
SRPT icon
14
Sarepta Therapeutics
SRPT
$1.63B
$62.5M 2.8%
800,000
-550,000
-41% -$42.1M
AGIO icon
15
Agios Pharmaceuticals
AGIO
$1.84B
$60.8M 2.73%
2,090,000
– –
RVMD icon
16
Revolution Medicines
RVMD
$38.8B
$60.5M 2.71%
2,370,000
– –
DNLI icon
17
Denali Therapeutics
DNLI
$3.67B
$48.3M 2.16%
1,500,000
– –
BEAM icon
18
Beam Therapeutics
BEAM
$2.66B
$46.9M 2.1%
818,820
– –
GBT
19
DELISTED
Global Blood Therapeutics, Inc.
GBT
$45.9M 2.06%
1,325,000
– –
TWST icon
20
Twist Bioscience
TWST
$5.97B
$43.5M 1.95%
880,000
+210,000
+31% +$11.6M
CDNA icon
21
CareDx
CDNA
$2.48B
$42.7M 1.91%
1,153,335
– –
TNYA icon
22
Tenaya Therapeutics
TNYA
$161M
$42.3M 1.89%
3,586,818
– –
TNGX icon
23
Tango Therapeutics
TNGX
$4.43B
$41.6M 1.87%
5,487,910
– –
IPSC icon
24
Century Therapeutics
IPSC
$353M
$40.4M 1.81%
3,206,380
– –
ONC
25
BeOne Medicines Ltd
ONC
$32.3B
$28.3M 1.27%
150,000
– –
1
2 3

Similar funds

MDSL
M.D. Sass LLC New York $1.32B AUM 16.01% 1-Year Est. Return
CP
Cumberland Partners Toronto, Ontario, Canada $1.32B AUM 27.83% 1-Year Est. Return
HCM
Hilton Capital Management Garden City, New York $1.32B AUM 15.59% 1-Year Est. Return
MIM
Marco Investment Management Atlanta, Georgia $1.33B AUM 32.43% 1-Year Est. Return
MRL
Mantle Ridge LP New York $1.33B AUM 11.36% 1-Year Est. Return
SWM
SHP Wealth Management Plymouth, Massachusetts $1.33B AUM
MCM
Mill Capital Management Concord, North Carolina $1.31B AUM 17.4% 1-Year Est. Return
B
BloombergSen Toronto, Ontario, Canada $1.31B AUM 8.32% 1-Year Est. Return

Casdin Capital's Q1 2022 Portfolio in Review

As of Q1 2022, Casdin Capital held 55 positions worth $2.23B, down 37% from $3.55B the previous quarter. Its ten largest holdings account for 55% of the portfolio.

Casdin Capital withdrew a net $302M in Q1 2022, closing 8 positions and reducing 7 holdings. Its most notable exit was Allogene Therapeutics, an estimated $39.5M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 95% a quarter earlier.

Against the trend, Casdin Capital opened a new position in Mirati Therapeutics, Inc. Common Stock worth $8.43M.

  • Casdin Capital's largest Q1 2022 buy was Mirati Therapeutics, Inc. Common Stock: 102,500 shares worth $8.43M.
  • Casdin Capital added most to Twist Bioscience in Q1 2022, an estimated $11.6M increase.
  • Casdin Capital's biggest Q1 2022 reduction was Codexis, cutting an estimated $83.5M.
  • Casdin Capital fully exited Allogene Therapeutics in Q1 2022, selling an estimated $39.5M.
  • Casdin Capital's ten largest holdings make up 55% of its $2.23B portfolio in Q1 2022.
  • Casdin Capital opened 2 new positions and closed 8 in Q1 2022.
  • Casdin Capital's portfolio value fell 37% quarter-over-quarter to $2.23B.

Based on Casdin Capital's 13F filing for Q1 2022, filed 16 May 2022.